1FDA Breakthrough Therapy Designation
2Registration-directed trial
3Imminent initiation
These studies are investigating treatments or outcomes that have not received approval from a health authority. We are working diligently to demonstrate the safety and efficacy of these products, but there is no guarantee that the outcome of these studies will result in approval. We invite you to review our expanded access policy.
Avutometinib (VS-6766)
RAF/MEK Clamp
Avutometinib (VS-6766) is a RAF/MEK Clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Defactinib (VS-6063)
Selective FAK Inhibitor
Defactinib (VS-6063) is a best-in-class selective FAK inhibitor that has been studied as a monotherapy and in combination in patients with solid tumors.
Investigator Sponsored Trials (IST)
We believe in the power of collaboration to help us push forward with new and promising cancer treatments. Our Verastem Oncology Investigator Sponsored Trial (IST) program strives to advance medical and scientific knowledge for our product candidates and disease states of interest. We welcome partnerships with researchers and sponsoring institutions that build on this mission.
Investigator Sponsored Trial Form
For additional details regarding our IST program or to submit a research request, please download, complete and submit the form below via email to verastem-IST@verastem.com.
Research Collaborations
Verastem Oncology also accepts proposals for preclinical research collaborations. For more information, please reach out to us at research@verastem.com.